+67.8%
ZETA vs MRNA
+511.3%
-443.5%
-40.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.1% | -2.2% | -1.8% | -4.0% |
| 7D | +2.7% | +5.5% | -2.8% | +2.5% |
| 30D | +15.8% | +158.7% | -142.9% | +7.3% |
| 3M | +35.4% | +182.1% | -146.7% | +23.1% |
| 6M | +67.1% | +151.8% | -84.7% | +55.2% |
| YTD | +54.1% | +393.6% | -339.5% | +24.2% |
| 1Y | +67.8% | +499.5% | -431.6% | +25.9% |
| All | +67.8% | +511.3% | -443.5% | +25.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling